Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;32(6):e94.
doi: 10.3802/jgo.2021.32.e94.

Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines

Hyun-Woong Cho #  1 , Kyung-Jin Min #  2 , Sang-Hoon Kwon  3 , Kidong Kim  4 , Sunghoon Kim  5 , Seok Ju Seong  6 , Yong Jung Song  7 , Keun Ho Lee  8 , Shin-Wha Lee  9 , Jeong-Won Lee  10 , Woong Ju  11 , Young Tae Kim  5 , Jae Kwan Lee  12
Affiliations
Review

Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines

Hyun-Woong Cho et al. J Gynecol Oncol. 2021 Nov.

Abstract

Since the human papillomavirus (HPV) vaccine guidelines were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2011, 2016, and 2019, several recent studies on the efficacy and safety of HPV vaccines in middle-aged women and men have been reported. Furthermore, there has been an ongoing debate regarding the efficacy of the HPV vaccine in women with prior HPV infection or who have undergone conization for cervical intraepithelial neoplasia (CIN). We searched and reviewed studies on the efficacy and safety of the HPV vaccine in middle-aged women and men and the efficacy of the HPV vaccine in patients infected with HPV and those who underwent conization for CIN. The KSGO updated their guidelines based on the results of the studies included in this review.

Keywords: Female; Male; Middle Aged; Papillomavirus Vaccines; Practice Guideline.

PubMed Disclaimer

Conflict of interest statement

Kyung-Jin Min and Seok Ju Seong serve as editors or editorial advisor of the Journal of Gynecologic Oncology (JGO), but have no role in the decision to publish this article. No other conflict of interest relevant to this article was reported.

Similar articles

See all similar articles

Cited by

References

    1. International Agency for Research on Cancer. A review of human carcinogens. Part B: biological agents. Lyon: IARC Working Group on the Evaluation of Carcinogenic Risks to Humans; 2009. pp. 255–314.
    1. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137:2060–2071. - PubMed
    1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890–907. - PubMed
    1. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–F23. - PubMed
    1. Ferris DG, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Mehlsen J, et al. 4-Valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years. Pediatrics. 2017;140:e20163947. - PubMed

Substances